A Case Study on IP-Backed Finance: Lessons from South Korea
A few years ago, if someone had told me you could walk into a bank, lay a patent on the
Welcome to Medicocristan: Why Mediocrity Is the Enemy of Breakthroughs
Medicocristan is a place where mediocrity reigns supreme. Its streets are orderly, its people are risk-averse, and its leaders champion
Consulting: The Final Refuge of the Corporate Castaway
It’s a tale as old as the severance check. A veteran employee—newly liberated from the corporate mothership—decides
The Problem with (Most) MBAs: When the Masters of the Universe Miss the Point
The MBA, that once-illustrious badge of business acumen, has long held a peculiar sway over boardrooms and balance sheets. It
Tail Risks in Drug Development: Case Studies and Lessons Learned
Drug development requires vast investments of capital and time. Even after extensive research and clinical testing, unforeseen safety problems or
Breaking the Mold: Harnessing Non-Conformity for Innovation and Advantage
Conformity is often the lubricant of social interaction. It smooths edges, creates predictability, and allows societies and organizations to function
A Case for Asking Better Questions
Louis Pasteur’s aphorism—“Chance favors only the prepared mind”—is often trotted out in the context of scientific breakthroughs
The Price of Neglect: Why Startups Must Care About Market Access
Startups face an uphill battle from securing funding to navigating the labyrinth of clinical trials and regulatory approvals, the journey
The Double-Speed Life: Podcasts, Audiobooks, and the Art of Listening
In the quiet moments of cycling to the office, chopping vegetables for dinner, or folding a week's worth
Why I Started Capital for Cures: Turning Frustration Into Action
A few months ago, I hit a wall—hard. I’d spent years working with biopharma companies, startups, and investors,
